EDNRB and pulmonary arterial hypertension: Its successor bosentan (Tracleer; Actelion, Allschwil, Switzerland), also a mixed ETA/ETB antagonist, was the first in class to be introduced into the clinic, initially for the treatment of pulmonary arterial hypertension (PAH) (Rubin et al., 2002).